Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02437136
Title Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in NSCLC With Expansion Cohorts in NSCLC and Melanoma
Recruitment Unknown status
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Syndax Pharmaceuticals
Indications

melanoma

lung non-small cell carcinoma

Therapies

Entinostat + Pembrolizumab

Age Groups: adult
Covered Countries USA


No variant requirements are available.